- About About
Medical Patient Resources Cannabis Care Certification Patient's Guide to Medical Cannabis Patient's Guide to CBD Talking to your doctor Become a Legal Medical Marijuana Patient The Medical Cannabis Patient’s Guide for U.S. Travel Guide to Using Medical Cannabis Cannabis Tincture, Salve, Butter and Oil Recipes Arthritis and Medical Cannabis Cancer and Medical Cannabis Chronic Pain and Medical Cannabis Gastrointestinal Disorders and Medical Cannabis HIV/AIDS and Medical Cannabis Movement Disorders and Medical Cannabis Multiple Sclerosis and Medical Cannabis Aging and Medical Cannabis Veterans and Medical Cannabis Medical Marijuana Conditions in Your Area Growing Cannabis Tracking Treatment & Gathering Data with Releaf App Medical Professional Resources Medical Cannabis Continuing Medical Education (CME) Cannabis Safety Medical Cannabis Research
- Legal Legal
Advocacy ASA Chapters Start an ASA Chapter Take Action Campaigns No Patient Left Behind End Pain, Not Lives Vote Medical Marijuana Medical Cannabis Advocate's Training Center Resources for Tabling and Lobby Days Strategic Planning Civics 101 Strategic Messaging Citizen Lobbying Participating in Implementation Movement Building Organizing a Demonstration Organizing Turnout for Civic Meetings Public Speaking Media 101 Patient's History of Medical Cannabis
Policy Policy Positions Model Federal Legislation Download Ending The Federal Conflict Public Comments by ASA Industry Standards Guide to Regulating Industry Standards Recognizing Science using the Data Quality Act Data Quality Act Briefs Fact Sheet on ASA's Data Quality Act Petition to HHS ASA Data Quality Act petition to HHS Information on Lawyers and Named Patients in the Data Quality Act Lawsuit Reports 2021 State of the States Cannabis and Cannabis Resin- Critical Review Preparation Document Medical Cannabis in America
- News News
- Join Join
The first broad marijuana policy statement by a state medical association has become a hot topic of conversation, repeatedly referring to the current federal approach as a “failed public health policy.” Indeed, the October 14, 2011 official policy statement by the California Medical Association (CMA) is gathering significant interest from medical marijuana advocates as well as the broader reform movement. While certain portions of the statement focus on full legalization, the CMA has geared its policy recommendations for those in Washington with the power to reschedule medical marijuana under the Controlled Substances Act (CSA).
The prevailing theme of the CMA policy is that marijuana’s current placement under Schedule I of the CSA has directly and severely hindered researchers from fully establishing marijuana’s medical value. Specifically, the CMA states without equivocation that:
[C]annabis must be moved out of its current Schedule I status.
Notably, the CMA points out that Schedule I classification of cannabis is the principle reason the growing body of international evidence in favor of medical marijuana’s efficacy has been limited in the U.S. to approximately one dozen clinical trials. The CMA ultimately recommends that:
Rescheduling cannabis will allow for further clinical research to determine the utility and risks of cannabis.
By urging the federal government to reclassify marijuana out of Schedule I, the CMA are in effect stating that marijuana does in fact have medical value. While some may choose to play up the reference to “risks,” the CMA was confident enough in medical marijuana’s safety to have issued an August 2011 “Physician Recommendation of Medical Cannabis,” which provides guidance to doctors on how they may treat their sick and dying patients with medical marijuana. In other words, the CMA has asserted that marijuana, even in the absence of FDA approval, is safe enough for physicians to recommend to their patients.
The CMA policy recommendation to reclassify marijuana is one that ASA not only supports, but has also been actively working to implement. As part of the Coalition for Rescheduling Cannabis (CRC), ASA has appealed a July 2011 denial by the DEA of the CRC rescheduling petition. With this policy statement by the CMA, patients and advocates have gained an important champion on the critical issue of federal rescheduling of marijuana. The question now becomes, will Washington officials listen to doctors' orders?